Bhringraj for Liver Health

Research suggests that Bhringraj (Eclipta alba/prostrata) and its key bioactive compound wedelolactone demonstrate consistent hepatoprotective effects across a range of preclinical models, with studies indicating benefits in contexts including fatty liver disease, alcohol-induced cirrhosis, viral hepatitis, liver fibrosis, cholestatic liver injury, and sepsis-induced liver damage. The body of evidence draws primarily from in vitro cell studies, animal models including mice, rats, zebrafish, and hamsters, and review articles synthesizing this preclinical work, with proposed mechanisms spanning anti-inflammatory pathways such as NF-κB inhibition, antifibrotic effects on hepatic stellate cells, bile acid regulation via the FXR axis, and oxidative stress pathways involving NRF2 and GPX4. All identified studies point in a supportive direction, and two reviews specifically confirm hepatoprotection as a well-documented pharmacological property of the plant and its constituents. However, a meaningful limitation of this evidence base is the near-complete absence of human clinical trials, meaning the translation of these findings to human liver health remains unestablished, and conclusions about efficacy in people should be drawn with caution.